KR100367948B1 - 백혈구부착분자vla-4에대한인체화된항체 - Google Patents

백혈구부착분자vla-4에대한인체화된항체 Download PDF

Info

Publication number
KR100367948B1
KR100367948B1 KR1019960703987A KR19960703987A KR100367948B1 KR 100367948 B1 KR100367948 B1 KR 100367948B1 KR 1019960703987 A KR1019960703987 A KR 1019960703987A KR 19960703987 A KR19960703987 A KR 19960703987A KR 100367948 B1 KR100367948 B1 KR 100367948B1
Authority
KR
South Korea
Prior art keywords
sequence
variable region
humanized
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019960703987A
Other languages
English (en)
Korean (ko)
Other versions
KR970700513A (ko
Inventor
매리 엠 벤디그
올리비에 제이 레제
조스 샐댄하
태런 에스. 존스
테드 에이 옛노크
Original Assignee
엘란 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘란 파마슈티칼스, 인크. filed Critical 엘란 파마슈티칼스, 인크.
Publication of KR970700513A publication Critical patent/KR970700513A/ko
Application granted granted Critical
Publication of KR100367948B1 publication Critical patent/KR100367948B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019960703987A 1994-01-25 1995-01-25 백혈구부착분자vla-4에대한인체화된항체 Expired - Lifetime KR100367948B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
US08/186269 1994-01-25

Publications (2)

Publication Number Publication Date
KR970700513A KR970700513A (ko) 1997-02-12
KR100367948B1 true KR100367948B1 (ko) 2003-07-12

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960703987A Expired - Lifetime KR100367948B1 (ko) 1994-01-25 1995-01-25 백혈구부착분자vla-4에대한인체화된항체

Country Status (21)

Country Link
EP (2) EP0804237B8 (cg-RX-API-DMAC7.html)
JP (5) JP4115517B2 (cg-RX-API-DMAC7.html)
KR (1) KR100367948B1 (cg-RX-API-DMAC7.html)
CN (1) CN1211123C (cg-RX-API-DMAC7.html)
AT (1) ATE333895T1 (cg-RX-API-DMAC7.html)
AU (1) AU703152B2 (cg-RX-API-DMAC7.html)
CA (1) CA2182013C (cg-RX-API-DMAC7.html)
DE (2) DE122006000043I1 (cg-RX-API-DMAC7.html)
DK (2) DK0804237T3 (cg-RX-API-DMAC7.html)
ES (2) ES2270425T3 (cg-RX-API-DMAC7.html)
FI (1) FI117509B (cg-RX-API-DMAC7.html)
FR (1) FR06C0024I2 (cg-RX-API-DMAC7.html)
HU (1) HU220799B1 (cg-RX-API-DMAC7.html)
LU (1) LU91271I2 (cg-RX-API-DMAC7.html)
MX (1) MX9602971A (cg-RX-API-DMAC7.html)
NL (1) NL300238I2 (cg-RX-API-DMAC7.html)
NO (3) NO319867B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ279730A (cg-RX-API-DMAC7.html)
PL (1) PL181827B1 (cg-RX-API-DMAC7.html)
PT (1) PT804237E (cg-RX-API-DMAC7.html)
WO (1) WO1995019790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
ATE161730T1 (de) * 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP2065050A1 (en) * 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CA2370814C (en) 1999-04-22 2010-07-06 Biogen, Inc. Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ300710B6 (cs) 1999-06-01 2009-07-22 Biogen Idec Ma Inc. Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2140881B1 (en) * 1999-12-16 2013-04-17 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
MXPA05006384A (es) * 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
EP1827491A4 (en) * 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
US20070122404A1 (en) * 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AR067011A1 (es) * 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
EP2221325B1 (en) 2007-12-13 2014-04-16 Tokuyama Corporation Photochromic curable composition
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
MX338969B (es) 2009-03-20 2016-05-06 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20140161794A1 (en) 2010-04-16 2014-06-12 Biogen Idec Ma Inc. Anti-vla-4 antibodies
ES2646717T3 (es) 2011-05-02 2017-12-15 Millennium Pharmaceuticals, Inc. Formulación para anticuerpo anti- 4 7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
WO2018091729A2 (en) 2016-11-21 2018-05-24 Zaklady Farmaceutyczne Polpharma Sa Aqueous pharmaceutical formulations
CN110997714B (zh) * 2017-02-17 2024-05-03 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007861A1 (en) * 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95501A (en) * 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
CA2129637C (en) * 1992-02-12 1999-05-04 Roy R. Lobb Treatment for inflammatory bowel disease
ATE182625T1 (de) * 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1990007861A1 (en) * 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature Vol.356:63-66 (1992. 3. 5) *

Also Published As

Publication number Publication date
NO2017040I2 (no) 2018-08-28
NZ279730A (en) 1998-04-27
CN1211123C (zh) 2005-07-20
EP1759709B1 (en) 2013-02-27
DE122006000043I1 (de) 2007-02-15
NO2006008I1 (no) 2006-08-07
NO2006008I2 (no) 2009-06-15
EP1759709A1 (en) 2007-03-07
DE69535133D1 (de) 2006-09-07
FI117509B (fi) 2006-11-15
HU9602019D0 (en) 1996-09-30
MX9602971A (es) 1998-01-31
FI962958L (fi) 1996-09-24
JP5487382B2 (ja) 2014-05-07
NL300238I1 (cg-RX-API-DMAC7.html) 2006-10-02
EP0804237B1 (en) 2006-07-26
EP0804237B8 (en) 2006-11-08
AU1696095A (en) 1995-08-08
CN1140413A (zh) 1997-01-15
EP0804237A1 (en) 1997-11-05
KR970700513A (ko) 1997-02-12
AU703152B2 (en) 1999-03-18
JPH09508272A (ja) 1997-08-26
EP0804237A4 (en) 2003-04-16
ATE333895T1 (de) 2006-08-15
JP2013165718A (ja) 2013-08-29
HU220799B1 (hu) 2002-05-28
NO319867B1 (no) 2005-09-26
DE69535133T2 (de) 2008-08-21
NO963097L (no) 1996-09-24
LU91271I2 (fr) 2006-10-02
FR06C0024I2 (fr) 2009-01-02
JP2009235078A (ja) 2009-10-15
ES2270425T3 (es) 2007-04-01
HUT75129A (en) 1997-04-28
PL315634A1 (en) 1996-11-25
PT804237E (pt) 2006-10-31
ES2424292T3 (es) 2013-09-30
JP2013173738A (ja) 2013-09-05
JP4115517B2 (ja) 2008-07-09
FR06C0024I1 (cg-RX-API-DMAC7.html) 2006-10-13
NL300238I2 (nl) 2007-05-01
WO1995019790A1 (en) 1995-07-27
DK0804237T3 (da) 2006-10-16
NO963097D0 (no) 1996-07-24
FI962958A0 (fi) 1996-07-24
JP2006045237A (ja) 2006-02-16
NO2017040I1 (no) 2017-08-01
DK1759709T3 (da) 2013-06-10
CA2182013C (en) 2007-07-17
CA2182013A1 (en) 1995-07-27
PL181827B1 (pl) 2001-09-28

Similar Documents

Publication Publication Date Title
KR100367948B1 (ko) 백혈구부착분자vla-4에대한인체화된항체
US5840299A (en) Humanized antibodies against leukocyte adhesion molecule VLA-4
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
CA2153692C (en) Recombinant anti-vla4 antibody molecules
HK1011031B (en) Recombinant anti-vla4 antibody molecules
HK1112193A (en) A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960724

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990525

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010530

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20010817

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20020430

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20010530

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20020730

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20020430

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20020930

Appeal identifier: 2002101002982

Request date: 20020730

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20020730

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20020730

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20011130

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19990525

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20020930

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20020902

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20021230

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20021231

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20051222

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20061226

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20071224

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20081224

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20091224

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20101208

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20111207

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20121130

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20131129

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20131129

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20141210

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20141210

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20150725

Termination category: Expiration of duration